<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296231</url>
  </required_header>
  <id_info>
    <org_study_id>200508714</org_study_id>
    <nct_id>NCT00296231</nct_id>
  </id_info>
  <brief_title>Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study</brief_title>
  <official_title>Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether application of high frequency ventilation
      through a nasal tube can lower blood carbon dioxide levels in stable preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prolonged mechanical ventilation is frequently needed to treat respiratory insufficiency and
      apnea in very low birthweight (VLBW, &lt;1500 g) preterm infants. Endotracheal intubation and
      mechanical ventilation carry many risks including potentially fatal air leaks and
      ventilator-associated pneumonias. Less-invasive methods of respiratory support are needed to
      minimize these risks while supporting the convalescing preterm infant. We propose to test
      the effectiveness of nasal high-frequency ventilation (NHFV) in stable neonates with mild
      respiratory acidosis who are dependent on nasal continuous positive airway pressure for
      respiratory support (CPAP). Nasal high frequency ventilation may be effective in decreasing
      rates of reintubation for apnea or respiratory insufficiency in VLBW infants. We will enroll
      60 stable VLBW infants who are currently being treated with nasal CPAP and who have mild
      respiratory acidosis. Twenty patients will be assigned to each ventilator under
      investigation. Nasal high frequency ventilation will be applied at the same mean airway
      pressure as the patients' previous CPAP support. The amplitude on nasal high frequency
      ventilation will be adjusted to achieve adequate shaking of the chest wall. Blood gas
      measurements, transcutaneous continuous pCO2 monitoring, continuous pulse oximetry, and
      chest x-rays will be used to assess safety and efficacy. Study power has been calculated to
      detect a difference (drop or rise) in partial pressure of CO2 (pCO2) equal to two-thirds of
      the standard deviation of pCO2 change reported in another study (van der Hoeven et al.,
      1998), which is a clinically relevant difference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pCO2 Measurements Post-intervention, as Compared to Pre-intervention Values</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Capillary partial pressure of CO2 (pCO2) was measured before and after 2 hours of nasal high frequency ventilatiion in a group of subjects. Each served as his/her own control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcutaneous CO2 Measurements as a Trend Throughout Intervention</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We used a transcutaneous CO2 monitor (TCOM) as a safety device throughout the study. We analyzed the change in TCOM readings recorded every 30 minutes (5 measurements) to determine safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Infant Respiratory Distress Syndrome</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Apnea of Prematurity</condition>
  <arm_group>
    <arm_group_label>Nasal High Frequency Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal high frequency ventilation</intervention_name>
    <description>use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.</description>
    <arm_group_label>Nasal High Frequency Ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  birthweight less than 1500 g

          -  Age &gt;7 days

          -  Free of severe intraventricular hemorrhage (Grade III-IV)

          -  requiring nasal continuous positive airway pressure with a stable compensated
             respiratory acidosis (pH 7.25 - 7.45, pCO2 &gt; 43 mm Hg),

          -  medically stable.

        Exclusion Criteria:

          -  major congenital anomalies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarah T Colaizy, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Iowa NICU</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 23, 2010</lastchanged_date>
  <firstreceived_date>February 22, 2006</firstreceived_date>
  <firstreceived_results_date>October 29, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Tarah Colaizy, MD, MPH</name_title>
    <organization>University of Iowa</organization>
  </responsible_party>
  <keyword>premature infants</keyword>
  <keyword>very low birthweight infants</keyword>
  <keyword>high frequency ventilation</keyword>
  <keyword>nasal ventilation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nassal High Frequency Ventilation</title>
          <description>Stable infants, born at less than 1501 g birthweight, who were at least 7 days of age and requiring nasal continuous positive airway pressure ventilatory support</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nassal High Frequency Ventilation</title>
          <description>Stable infants, born at less than 1501 g birthweight, who were at least 7 days of age and requiring nasal continuous positive airway pressure ventilatory support</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.5" lower_limit="18" upper_limit="147"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>pCO2 Measurements Post-intervention, as Compared to Pre-intervention Values</title>
        <description>Capillary partial pressure of CO2 (pCO2) was measured before and after 2 hours of nasal high frequency ventilatiion in a group of subjects. Each served as his/her own control.</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nassal High Frequency Ventilation</title>
            <description>Stable infants, born at less than 1501 g birthweight, who were at least 7 days of age and requiring nasal continuous positive airway pressure ventilatory support</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>pCO2 Measurements Post-intervention, as Compared to Pre-intervention Values</title>
            <description>Capillary partial pressure of CO2 (pCO2) was measured before and after 2 hours of nasal high frequency ventilatiion in a group of subjects. Each served as his/her own control.</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>pre-nasal high frequency ventilation pCO2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50" spread="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>post-nasal high frequency ventilation pCO2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45" spread="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Paired Student's t-test was used to compare pre and post intervention pCO2 values.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.011</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transcutaneous CO2 Measurements as a Trend Throughout Intervention</title>
        <description>We used a transcutaneous CO2 monitor (TCOM) as a safety device throughout the study. We analyzed the change in TCOM readings recorded every 30 minutes (5 measurements) to determine safety</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Nassal High Frequency Ventilation</title>
            <description>Stable infants, born at less than 1501 g birthweight, who were at least 7 days of age and requiring nasal continuous positive airway pressure ventilatory support</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Transcutaneous CO2 Measurements as a Trend Throughout Intervention</title>
            <description>We used a transcutaneous CO2 monitor (TCOM) as a safety device throughout the study. We analyzed the change in TCOM readings recorded every 30 minutes (5 measurements) to determine safety</description>
            <units>torr</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>pre-nasal high frequency TCOM</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47" spread="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>post-nasal high frequency ventilation TCOM</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="46" spread="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nassal High Frequency Ventilation</title>
          <description>Stable infants, born at less than 1501 g birthweight, who were at least 7 days of age and requiring nasal continuous positive airway pressure ventilatory support</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tarah Colaizy</name_or_title>
      <organization>University of Iowa</organization>
      <email>tarah-colaizy@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
